Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578198 | 0.84 | MAOB (0.43) | MAOBMAOAACHEANO1 | |
| SCHEMBL1578651 | 0.83 | MAOB (0.59) | MAOBMAOAACHE | |
| SCHEMBL4323959 | 0.80 | MAOB (0.54) | MAOBMAOAACHE | |
| SCHEMBL4322263 | 0.80 | MAOB (0.53) | MAOBMAOAACHE | |
| SCHEMBL4319284 | 0.79 | MAOB (0.65) | MAOBMAOAACHE | |
| SCHEMBL5382147 | 0.78 | MAOB (0.66) | MAOBMAOA | |
| SCHEMBL1578355 | 0.78 | MAOB (0.50) | MAOBMAOAACHEANO1PPARA | |
| SCHEMBL25947183 | 0.77 | MAOB (0.50) | MAOB | |
| SCHEMBL4323948 | 0.77 | MAOB (0.53) | MAOBMAOA | |
| SCHEMBL25947185 | 0.77 | MAOB (0.57) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492588-B2 | Benzyloxy anilide derivatives useful as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120329869-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL | 2012-12-27 | — | — | US | disclosed |
| US-8188314-B2 | Benzyloxy anilide derivatives useful as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090326059-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329869-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCND2, KCNB2, KCNAB1 | MAOB 549/4885MAOA 756/4885ACHE 1604/4885 |
| US-20090326059-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCND2, KCNB2, KCNAB1 | MAOB 549/4885MAOA 756/4885ACHE 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.